A N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability and its preparation and application
Genetic engineering technology replaces the amino acid sequence of N-acetylglucosidase and constructs the mutant Ea2C, which solves the problem of poor thermal stability of existing enzymes, achieves the improvement of enzyme activity and thermal stability improvement, and is suitable for functional food production , reducing application costs.
Patent Information
- Application Number
- CN202410096874.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-01-24
AI Technical Summary
The thermal stability of existing N-acetylglucosamine is poor, which limits the application of its functional acetylglucosamine, and improving thermal stability usually loses enzyme activity.
Through genetic engineering technology, the second position of glutamate in the amino acid sequence of the wild enzyme HJ5Nag is replaced with cysteine to construct an N-acetylglucosidase mutant Ea2C that synergistically improves enzyme activity and thermal stability, and through The recombinant expression vector and strain express the mutant in E. coli BL21.
The enzyme activity of mutant Ea2C on both substrates was increased by 1.16-fold and 1.12-fold, and the enzyme activity was maintained at 37°C for 60 minutes, which was about 40% higher than that of wild-type, reducing application costs. Suitable for functional food production and processing.
Smart Images

Figure CN118086249B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a mutant, in particular to an N-acetylglucosaminidase mutant capable of synergistically improving enzyme activity and thermal stability, and the preparation and application thereof. Background Art
[0002] Glucosamine is one of the basic components of important polysaccharides in biological cells, and its edible safety has been widely recognized. It can be used clinically to slow the release of inflammatory joint diseases, promote the healing of cartilage damage, improve intestinal digestion and absorption, promote growth, and regulate the growth and development of the fetal heart; it can also be used as an adjuvant for active ingredients in medicine and to produce sialic acid precursors. N-acetylglucosaminidases (GlcNAcases, N-acetyl-glucosaminidases, EC 3.2.1.52) can cooperate with chitinase to degrade environmental waste rich in chitin (such as shrimp shells or fungal mycelium, etc.), and cut the non-reducing ends of chitosan oligosaccharides one by one to produce functional acetylglucosamine.
[0003] Existing document 1 (Zhang et al. Appl Microbiol Biot, 2018, 102 (1): 93-103) discloses that the low enzymatic activity and poor thermal stability of N-acetylglucosamine enzymes affect their production of functional acetylglucosamine. HJ5Nag has excellent properties such as resistance to product inhibition and high activity, but its thermal stability is poor, and only 11% of the enzyme activity remains after treatment at 37°C for 1h, which greatly limits the application of its functional acetylglucosamine. Generally, the improvement of the thermal stability of an enzyme will result in the loss of some enzyme activity. Therefore, the use of protein engineering to improve the thermal stability of the wild enzyme HJ5Nag without losing enzyme activity is beneficial to its application in the fields of functional food production and processing, and has important application significance and economic value. Summary of the invention
[0004] The purpose of the present invention is to provide an N-acetylglucosamine enzyme mutant that synergistically improves enzyme activity and thermal stability, and its preparation and application, which solves the problem that the thermal stability of the existing high specific activity HJ5Nag is poor, which limits the application of its functional acetylglucosamine.
[0005] In order to achieve the above object, the present invention provides an N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability. The amino acid sequence of the mutant is shown in SEQ ID NO.1.
[0006] The present invention provides a gene encoding an N-acetylglucosaminidase mutant capable of synergistically improving enzyme activity and thermal stability, and the nucleotide sequence of the gene encoding the mutant is shown in SEQ ID NO.2.
[0007] The present invention provides a recombinant expression vector comprising a gene encoding an N-acetylglucosaminidase mutant capable of synergistically improving enzyme activity and thermal stability.
[0008] Preferably, the recombinant expression vector includes pET series plasmids.
[0009] The present invention provides a recombinant expression bacterium comprising a gene encoding an N-acetylglucosaminidase mutant capable of synergistically improving enzyme activity and thermal stability as described above.
[0010] Preferably, the recombinant expression bacteria is selected from Escherichia coli BL21 (DE3).
[0011] The present invention provides a method for preparing an N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability. The method comprises replacing the glutamic acid at position 2 in the amino acid sequence of the N-acetylglucosaminidase as shown in SEQ ID NO.3 with cysteine.
[0012] The present invention provides an N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability or an encoding gene of the N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability in the production and processing of functional foods.
[0013] The present invention provides an application of the recombinant vector in the production and processing of functional foods.
[0014] The present invention provides an application of the recombinant expression bacteria in the production and processing of functional foods.
[0015] The present invention discloses an N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability, and its preparation and application, which solves the problem that the thermal stability of the existing high specific activity HJ5Nag is poor, which limits the application of its functional acetylglucosamine, and has the following advantages:
[0016] The present invention uses genetic engineering technology to provide an N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability. The mutant has enzyme activities of 540.3U / mg and 184.2U / mg for pNPGlcNA and natural substrate chitosan oligosaccharide, respectively. Compared with the wild enzyme opt-HJ5NagNC, the mutant enzyme activity is increased by 1.16 times and 1.12 times. After being treated at 37°C for 60 minutes, the enzyme activity can still be maintained at more than 50%, which is about 40% higher than that of the wild type under the same heat treatment conditions, reducing the application cost and providing a guarantee for its application in the field of functional food production and processing. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is a diagram showing the SDS-PAGE analysis results of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention.
[0018] Figure 2 This is a diagram showing the results of enzyme activity assays of the wild enzyme opt-HJ5NagNC and mutant Ea2C provided by the present invention using two substrates, pNPGlcNA and chito-oligosaccharide.
[0019] Figure 3 This is a graph showing the results of determining the optimum temperatures of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention.
[0020] Figure 4 This is a graph showing the results of the temperature stability test at 37°C of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention.
[0021] Figure 5 This is a graph showing the results of determining the optimum pH of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention. DETAILED DESCRIPTION
[0022] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] The recombinant N-acetylglucosaminidase described in the embodiment of the present invention is the expression product of wild-type N-acetylglucosaminidase HJ5Nag (GenBank accession number ARJ33352) inserted into the recombination region of the pEasy-E2 expression vector, and its amino acid sequence is shown in SEQ ID NO.3.
[0024] The present invention uses some experimental materials and reagents adopted in the following examples:
[0025] 1. Strains and vectors: Escherichia coli BL21 (DE3) and expression vector pET-22b (+) were purchased from Novagen.
[0026] 2. Enzymes and other biochemical reagents: Nickel-NTA Agarose was purchased from QIAGEN, QuickMutation TMThe gene site-directed mutagenesis kit was purchased from Shanghai Biyuntian Company, the BCA protein quantification kit was purchased from Shanghai Yazyme Biotechnology Co., Ltd., p-nitrophenol-β-N-acetylglucosamine (pNPGlcNAc) was purchased from Shanghai Yuanye Company, and chitosan oligosaccharide was purchased from Qingdao Bozhihuili Biotechnology Co., Ltd. The others were domestic reagents (all of which can be purchased from ordinary biochemical reagent companies).
[0027] 3. Culture medium
[0028] LB medium: 10 g peptone, 5 g yeast extract, 10 g sodium chloride, add distilled water to 1000 mL, pH natural (about 7). Solid medium is based on this and 2.0% (w / v) agar is added.
[0029] The molecular biology experimental methods not described in detail in this example are all carried out according to the specific methods listed in the book "Molecular Cloning Experiment Guide" (3rd edition) by J. Sambrook, or according to the kits and product instructions.
[0030] Example 1 Construction and transformation of expression vector of N-acetylglucosaminidase mutant (Ea2C) with synergistically improved enzyme activity and thermal stability
[0031] The nucleotide sequence of the N-acetylglucosaminidase gene hj5nag, whose GenBank accession number is KX400857, deletes the signal peptide NRRRGRAIAAATVLAASLA (AATCGTCGCCGAGGACGGGCCATCGCCGCCGCCACGGTGCTCGCCGCGTC GCTGGCG), and because its GC content is as high as 72% and there are more hairpin structures, codon optimization is performed, and at the same time, a coding sequence 7 is introduced after its start codon, and its nucleotide sequence is shown in SEQ ID NO.7, and a coding sequence 8 is introduced before its stop codon, and its nucleotide sequence is shown in SEQ ID NO.8, as shown in detail as follows:
[0032] Since the N-acetylglucosaminidase gene opt-hj5nagNC used in this example is constructed between the NdeI and XhoI restriction sites in the vector pET-22b(+), and the ATG on NdeI is used as the start codon, the introduced coding sequences 7 and 8 correspond to the nucleotide fragments of the amino acid fragments 'ELAL and KGQF', respectively, to eliminate the change in the recombinant N-acetylglucosaminidase expression sequence caused by replacing the original vector pEasy-E2 with the current vector pET-22b(+). After optimization, the N-acetylglucosaminidase optimized gene opt-hj5nagNC with a nucleotide sequence as shown in SEQ ID NO.4 was obtained. The optimized gene opt-hj5nagNC was synthesized by Suzhou Hongxun Biotechnology Co., Ltd., and a recombinant expression plasmid pET22b-opt-hj5nagNC containing the optimized gene opt-hj5nagNC was constructed, and the recombinant expression plasmid pET22b-opt-hj5nagNC was transferred into Escherichia coli BL21 (DE3) to obtain a recombinant expression bacterium containing the optimized gene. The protein expressed by the optimized gene is the optimized wild enzyme opt-HJ5NagNC, which is the same as the amino acid HJ5Nag sequence of the recombinant N-acetylglucosaminidase in the pEasy-E2 vector, and its amino acid sequence is shown in SEQ ID NO.3.
[0033] The introduced coding sequence is as follows (5'→3'):
[0034] Coding sequence 7 (SEQ ID NO. 7): GAATTGGCACTT.
[0035] Coding sequence 8 (SEQ ID NO. 8): AAGGGACAATTC.
[0036] 1. According to the optimized wild enzyme opt-hj5nagNC sequence shown in SEQ ID NO.4 and the plasmid pET-22b-opt-hj5nagNC, the recombination primers F and R were designed using CE Design software. The specific sequences are as follows:
[0037] The recombination primer sequence is as follows (5'→3'):
[0038] F (SEQ ID NO.5):
[0039] ATGTGTTTGGCACTTGGTTGTAGTCCGGCAGC.
[0040] R (SEQ ID NO.6):
[0041] CCAAGTGCCAAACACATATGTATATCTCCTTCTTAAAGTTAAACAAA.
[0042] According to QuickMutation TM According to the manufacturer's instructions of the gene site-directed mutagenesis kit, PCR amplification was performed using the plasmid pET-22b-opt-hj5nagNC as a template to obtain the PCR product of pET-22b-Ea2C. The reaction procedure of the PCR amplification was as follows: pre-denaturation at 95°C for 30 min; then denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, extension at 68°C for 7 min, for a total of 20 cycles; extension and completion at 68°C for 15 min; and temporary storage at 4°C for 30 min.
[0043] 2. After the PCR reaction, add 1 μL of DpnI directly to the PCR reaction system, mix well, and incubate in a 37°C water bath for 5 minutes. After DpnI digestion, it can be used directly for transformation or stored at -20°C for later use.
[0044] 3. Transformation and identification: The PCR digestion product was transformed into Escherichia coli BL21 (DE3) competent cells by heat shock method. After picking a single colony for culture and preservation, a recombinant expression bacterium containing the expression vector pET-22b-Ea2C was obtained. It was further confirmed by sequencing by Beijing Qingke Biotechnology Co., Ltd. that the nucleotide sequence of the mutant Ea2C encoding gene is shown in SEQ ID NO.2. At the same time, it can be seen that the amino acid sequence of the mutant Ea2C is shown in SEQ ID NO.1. Compared with the optimized wild enzyme opt-HJ5NagNC (SEQ ID NO.3) amino acid sequence, Ea2C replaces the glutamic acid at the second position with cysteine.
[0045] Example 2 Preparation of wild enzyme opt-HJ5NagNC and mutant Ea2C
[0046] The recombinant expression strains containing the wild enzyme opt-HJ5NagNC and mutant Ea2C encoding genes were inoculated in LB (containing 100 μg mL -1 Ampicillin) culture medium, 37 ° C, 180 rpm overnight culture, to obtain an activated bacterial solution.
[0047] The activated bacterial solution was inoculated into fresh LB (containing 100 μg mL -1 Ampicillin) culture medium, culture with rapid shaking at 37°C and 180 rpm constant temperature shaker for about 2 to 3 hours. 600When the pH reaches between 0.6 and 1.0, add IPTG at a final concentration of 0.7mM for induction, and culture in a constant temperature shaker at 20℃ and 160rpm for about 20h. Centrifuge the induced bacterial solution in a low-temperature centrifuge at 4℃ and 6000rpm for 10min to collect the bacteria. Suspend the bacteria with an appropriate amount of pH=7.0McIlvaine buffer, and then ultrasonically break the bacteria in a low-temperature water bath. After the above intracellular concentrated crude enzyme solution is centrifuged at 12000rpm for 10min, the supernatant is aspirated and the target protein is affinity and eluted with Nickel-NTAAgarose and 0-500mM imidazole respectively.
[0048] like Figure 1 As shown in the figure, the SDS-PAGE analysis result of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention, wherein M is a protein marker; the crude enzyme solution of opt-HJ5NagNC is the unpurified wild enzyme opt-HJ5NagNC; opt-HJ5NagNC is the purified wild enzyme opt-HJ5NagNC; and Ea2C is the purified mutant Ea2C. Figure 1 The results showed that both the wild enzyme opt-HJ5NagNC and the mutant Ea2C were purified and the product was a single band.
[0049] Example 3 Determination of properties of wild enzyme opt-HJ5NagNC and mutant Ea2C
[0050] 1. Activity Analysis of Purified Wild-type Enzyme opt-HJ5NagNC and Mutant Ea2C
[0051] Method for determining the activity of p-nitrophenol (pNP): dissolve the substrate pNPGlcNAc in buffer to a final concentration of 2 mM; the reaction system contains 50 μL of enzyme solution and 450 μL of substrate; the substrate is preheated at the reaction temperature for 5 min, then the enzyme solution is added to react for 10 min, and then 2 mL of 1 M Na2CO3 is added to terminate the reaction. After cooling to room temperature, the OD value is measured at a wavelength of 405 nm; 1 enzyme activity unit (U) is defined as the amount of enzyme required to decompose the substrate to produce 1 μmol pNP per minute under given conditions.
[0052] 3,5-Dinitrosalicylic acid (DNS) activity assay method: Dissolve the substrate chitosan oligosaccharide in buffer to a final concentration of 0.5% (w / v); the reaction system contains 20 μL of an appropriate amount of enzyme solution and 180 μL of substrate; the substrate is preheated at the reaction temperature for 5 min, reacted for 10 min after the addition of the enzyme solution, and then 300 μL of DNS is added to terminate the reaction, boiled in boiling water for 5 min, and the OD value is measured at a wavelength of 540 nm after cooling to room temperature; 1 enzyme activity unit (U) is defined as the amount of enzyme required to decompose the substrate to produce 1 μmol of reducing sugar (in terms of acetylglucosamine) per minute under given conditions.
[0053] The activity results of the wild enzyme opt-HJ5NagNC and the mutant Ea2C at 30°C and pH 6 are shown in Tables 1 and Figure 2 As shown in Table 1 and Figure 2 The results showed that the enzyme activity of mutant Ea2C on two substrates, pNPGlcNAc and chitosan oligosaccharide, was increased by 1.16 and 1.12 times respectively compared with the wild enzyme opt-HJ5NagNC.
[0054] Table 1 Activity of wild enzymes opt-HJ5NagNC and Ea2C
[0055]
[0056] 2. Thermal activity and thermal stability of purified wild-type enzyme opt-HJ5NagNC and mutant Ea2C
[0057] The optimal temperature of the wild enzyme and mutant was determined by a two-step method. The activity was measured at each temperature interval of 10°C for the first time, and at the temperature point with the highest activity and the temperature points 5°C to the left and right for the second time. The measurement results can be accurately verified when the sample volume is basically unchanged. In a buffer solution of pH = 6.0, the enzymatic reaction was first carried out at 0-60°C, and the enzyme activity was measured every 10°C from 0°C. It was found that the wild enzyme opt-HJ5NagNC and the mutant Ea2C had the highest enzyme activity at 40°C. Then, the enzyme activity of the wild enzyme and mutant was measured at 35°C, 40°C and 45°C in a buffer solution of pH = 6.0.
[0058] like Figure 3 As shown in the figure, the optimum temperature determination result of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention. Figure 3 It can be seen that the optimum temperatures of the wild enzyme opt-HJ5NagNC and the mutant Ea2C are 45℃ and 40℃, respectively.
[0059] Enzyme thermal stability determination: After the same unit of wild enzyme and mutant were treated at 37°C for 1 hour, samples were taken at 10min, 20min, 30min and 60min of heat treatment, and the residual enzyme activity of the samples was measured at pH = 6.0 and 30°C, with the enzyme activity of the untreated enzyme solution as the control. Using pNPGlcNAc as the substrate, the reaction was carried out for 10min, and the residual enzyme activity of the purified wild enzyme opt-HJ5NagNC and mutant Ea2C was measured.
[0060] like Figure 4 As shown in the figure, the temperature stability test result of the wild enzyme opt-HJ5NagNC and the mutant Ea2C at 37°C provided by the present invention is shown in the figure. Figure 4 The results showed that the mutant Ea2C was significantly more stable than the wild enzyme opt-HJ5NagNC at 37°C.
[0061] 3. Determination of the optimal pH of the purified wild-type enzyme opt-HJ5NagNC and mutant Ea2C
[0062] The optimal pH of the wild enzyme and mutant was determined by a two-step method. The activity was measured at every pH unit point, and the second time at the pH unit point with the highest activity and the points 0.5 pH units to the left and right. The results can be accurately and verified when the sample volume is basically unchanged. At 30°C, the buffer was 0.1M cilvaine buffer (pH = 5.0-8.0) and 0.1M glycine-NaOH (pH = 9.0). pNPGlcNAc was used as a substrate and the reaction lasted for 10 minutes to determine the enzymatic properties of the purified N-acetylglucosaminidase. First, the enzyme solution was placed in a buffer solution of pH = 5.0, 6.0, 7.0, 8.0, and 9.0 for the above-mentioned enzymatic reaction. It was found that the wild enzyme opt-HJ5NagNC and the mutant Ea2C both had the highest enzyme activity at pH 6.0. The wild enzyme and the mutant were then measured in buffer solutions of pH = 5.5, 6.0, and 6.5, respectively.
[0063] like Figure 5 As shown in the figure, the optimum pH determination results of the wild enzyme opt-HJ5NagNC and the mutant Ea2C provided by the present invention. Figure 5 It can be seen that the optimal pH of the wild enzyme opt-HJ5NagNC and the mutant Ea2C is 6.0, and the mutant Ea2C can maintain more than 80% of the enzyme activity at a pH of 6.0-8.0.
[0064] In summary, the present invention utilizes genetic engineering technology to mutate the second glutamic acid at the N-terminus of the wild enzyme opt-HJ5NagNC to cysteine, and obtains the mutant Ea2C. The enzyme activities of the mutant for the two substrates pNPGlcNA and chitosan oligosaccharide are 540.3U / mg and 184.2U / mg, respectively. Compared with the wild enzyme opt-HJ5NagNC, the enzyme activity of the mutant is increased by 1.16 times and 1.12 times. And under the pNPGlcNA substrate, after being treated at 37°C for 60 minutes, the enzyme activity can still be maintained at more than 50%, which is about 40% higher than the enzyme activity of the wild enzyme treated under the same conditions. The N-acetylglucosaminidase mutant of the present invention reduces the application cost and has broad application prospects in the fields of medicine or functional foods.
[0065] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.
Claims
1. A mutant of N-acetylglucosaminidase that synergistically improves enzyme activity and thermal stability, characterized in that: The amino acid sequence of the mutant is shown in SEQ ID NO.
1.
2. A gene encoding a mutant of N-acetylglucosaminidase that synergistically improves enzyme activity and thermal stability as claimed in claim 1, characterized in that: The nucleotide sequence of the coding gene is shown in SEQ ID NO.
2.
3. A recombinant expression vector comprising a gene encoding the N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability as claimed in claim 2.
4. The recombinant expression vector according to claim 3, characterized in that The recombinant expression vector includes pET series plasmids.
5. A recombinant expression bacterium comprising a gene encoding the N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability as claimed in claim 2.
6. The recombinant expression bacteria according to claim 5, characterized in that: The recombinant expression bacteria are selected from Escherichia coli BL21 (DE3).
7. A method for preparing an N-acetylglucosaminidase mutant that synergistically improves enzyme activity and thermal stability, characterized in that: The method comprises replacing the glutamic acid at position 2 in the amino acid sequence of N-acetylglucosaminidase as shown in SEQ ID NO.3 with cysteine.
8. Use of the N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability as claimed in claim 1 or the encoding gene of the N-acetylglucosaminidase mutant with synergistically improved enzyme activity and thermal stability as claimed in claim 2 in the production and processing of functional foods.
9. Use of the recombinant vector as claimed in claim 3 in the production and processing of functional foods.
10. Use of the recombinant expression bacteria as claimed in claim 5 in the production and processing of functional foods.
